Pure Global
NCT06338462

Cali Sin Tos Aim 2

Mobile Health and Oral Testing to Optimize Tuberculosis Contact Tracing in Colombia
Yale University·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Tuberculosis
Drug/Device/Intervention
Chatbot
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Yale University
Location
Cali, Colombia
Timeline & enrollment
Phase
N/A
Start date
May 01, 2024
End date
May 01, 2025
Enrollment
120 participants
Primary outcome

Implementation of the mHealth strategy to assess feasibility.,Oral specimen collection to assess feasibility.

Summary

The overall objective of this Aim is to design and iteratively adapt a home-based, mHealth-
 and oral testing facilitated strategy for implementing tuberculosis (TB) contact tracing in
 Cali, Colombia. Investigators will employ an iterative, community-engaged, participatory
 co-design process to optimize the feasibility, acceptability, usability, and appropriateness
 of the mobile health (mHealth) and oral testing strategy, in preparation for a future,
 appropriately powered implementation-effectiveness trial.
 
 This protocol includes the baseline contact tracing protocol and the procedures for
 determining adaptations to the mHealth strategy (i.e., nominal group technique).

ICD-10 classifications
TuberculosisLatent tuberculosisTuberculosis of other organsCongenital tuberculosisSequelae of tuberculosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06338462
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06338462 through Pure Global AI's free database. This phase not specified trial is sponsored by Yale University and is currently Not yet recruiting. The study focuses on Tuberculosis. Target enrollment is 120 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.